390 related articles for article (PubMed ID: 19530963)
1. Pharmacogenomics of adverse drug reactions: practical applications and perspectives.
Becquemont L
Pharmacogenomics; 2009 Jun; 10(6):961-9. PubMed ID: 19530963
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomics: historical perspective and current status.
Charlab R; Zhang L
Methods Mol Biol; 2013; 1015():3-22. PubMed ID: 23824846
[TBL] [Abstract][Full Text] [Related]
3. Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics.
Becquemont L; Alfirevic A; Amstutz U; Brauch H; Jacqz-Aigrain E; Laurent-Puig P; Molina MA; Niemi M; Schwab M; Somogyi AA; Thervet E; Maitland-van der Zee AH; van Kuilenburg AB; van Schaik RH; Verstuyft C; Wadelius M; Daly AK
Pharmacogenomics; 2011 Jan; 12(1):113-24. PubMed ID: 21174626
[TBL] [Abstract][Full Text] [Related]
4. The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety.
Roses AD
Neuropsychopharmacology; 2009 Jan; 34(1):6-17. PubMed ID: 18923406
[TBL] [Abstract][Full Text] [Related]
5. The contribution of pharmacogenetics to pharmacovigilance.
Bondon-Guitton E; Despas F; Becquemont L
Therapie; 2016 Apr; 71(2):223-8. PubMed ID: 27080842
[TBL] [Abstract][Full Text] [Related]
6. [Challenge in genome-wide association study for establishment of personalized medicine: focusing on the pharmacogenomics of warfarin and carbamazepine].
Mushiroda T
Rinsho Byori; 2013 May; 61(5):422-7. PubMed ID: 23947182
[TBL] [Abstract][Full Text] [Related]
7. Methodological and statistical issues in pharmacogenomics.
Peters BJ; Rodin AS; de Boer A; Maitland-van der Zee AH
J Pharm Pharmacol; 2010 Feb; 62(2):161-6. PubMed ID: 20487194
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenomics and adverse drug reactions in diagnostic and clinical practice.
Manolopoulos VG
Clin Chem Lab Med; 2007; 45(7):801-14. PubMed ID: 17617019
[TBL] [Abstract][Full Text] [Related]
9. Progress in understanding the genomic basis for adverse drug reactions: a comprehensive review and focus on the role of ethnicity.
Chan SL; Jin S; Loh M; Brunham LR
Pharmacogenomics; 2015; 16(10):1161-78. PubMed ID: 25978008
[TBL] [Abstract][Full Text] [Related]
10. Personalized pharmacogenomics profiling using whole-genome sequencing.
Mizzi C; Peters B; Mitropoulou C; Mitropoulos K; Katsila T; Agarwal MR; van Schaik RH; Drmanac R; Borg J; Patrinos GP
Pharmacogenomics; 2014 Jun; 15(9):1223-34. PubMed ID: 25141897
[TBL] [Abstract][Full Text] [Related]
11. Perception of the usefulness of drug/gene pairs and barriers for pharmacogenomics in Latin America.
Quinones LA; Lavanderos MA; Cayun JP; Garcia-Martin E; Agundez JA; Caceres DD; Roco AM; Morales JE; Herrera L; Encina G; Isaza CA; Redal MA; Larovere L; Soria NW; Eslava-Schmalbach J; Castaneda-Hernandez G; Lopez-Cortes A; Magno LA; Lopez M; Chiurillo MA; Rodeiro I; Castro de Guerra D; Teran E; Estevez-Carrizo F; Lares-Assef I
Curr Drug Metab; 2014 Feb; 15(2):202-8. PubMed ID: 24524664
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomic profiling in postmarketing surveillance: prospects and challenges.
Issa AM
Pharmacogenomics; 2003 Sep; 4(5):647-55. PubMed ID: 12943471
[TBL] [Abstract][Full Text] [Related]
13. HLA: a pharmacogenomics success story.
Becquemont L
Pharmacogenomics; 2010 Mar; 11(3):277-81. PubMed ID: 20235781
[No Abstract] [Full Text] [Related]
14. Are Randomized Controlled Trials Necessary to Establish the Value of Implementing Pharmacogenomics in the Clinic?
Huddart R; Sangkuhl K; Whirl-Carrillo M; Klein TE
Clin Pharmacol Ther; 2019 Aug; 106(2):284-286. PubMed ID: 30977517
[No Abstract] [Full Text] [Related]
15. Interpreting the clinical utility of a pharmacogenomic marker based on observational association studies.
Sorich MJ; Coory M
Pharmacogenomics J; 2014 Feb; 14(1):1-5. PubMed ID: 24018622
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenomics and active surveillance for serious adverse drug reactions in children.
Loo TT; Ross CJ; Sistonen J; Visscher H; Madadi P; Koren G; Hayden MR; Carleton BC
Pharmacogenomics; 2010 Sep; 11(9):1269-85. PubMed ID: 20860467
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics of allopurinol--making an old drug safer.
Lam MP; Yeung CK; Cheung BM
J Clin Pharmacol; 2013 Jul; 53(7):675-9. PubMed ID: 23381951
[TBL] [Abstract][Full Text] [Related]
18. Availability of pharmacogenetic and pharmacogenomic information in anticancer drug monographs in France: personalized cancer therapy.
Albertini L; Siest G; Jeannesson E; Visvikis-Siest S
Pharmacogenomics; 2011 May; 12(5):681-91. PubMed ID: 21619430
[TBL] [Abstract][Full Text] [Related]
19. The Canadian Pharmacogenomics Network for Drug Safety: a model for safety pharmacology.
Ross CJ; Visscher H; Sistonen J; Brunham LR; Pussegoda K; Loo TT; Rieder MJ; Koren G; Carleton BC; Hayden MR;
Thyroid; 2010 Jul; 20(7):681-7. PubMed ID: 20578893
[TBL] [Abstract][Full Text] [Related]
20. Drug-induced hypersensitivity reactions and pharmacogenomics: past, present and future.
Alfirevic A; Pirmohamed M
Pharmacogenomics; 2010 Apr; 11(4):497-9. PubMed ID: 20350129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
